Dr. Kansagra on Updates With CAR T-Cell Therapy in Hematologic Cancers

Video

Ankit Kansagra, MD, discusses key updates with CAR T-cell therapy in hematologic cancers.

Ankit Kansagra, MD, assistant professor in the Department of Internal Medicine at Harold C. Simmons Comprehensive Cancer Center of UT Southwestern Medical Center, discusses key updates with CAR T-cell therapy in hematologic cancers.

Many fantastic updates have been presented in CAR T-cell therapy in this space, with real-world evidence, says Kansagra. One of these updates has been seen with axicabtagene ciloleucel (axi-cel; Yescarta), which has been out for about 2 years now. More than 500 patients countrywide in more than 50 institutions were treated with this product and were monitored by the Center for International Blood and Marrow Transplant Research. Investigators noticed that this therapy was very efficacious, which is the most important information from the update, adds Kansagra. Sometimes, a drugmight appear to be efficacious in clinical trials but that activity is not replicated in the real world. The toxicity or safety profile of the agent in the real-world setting was also very comparable to what had been reported in clinical trials.

Another thing learned in the clinical setting is that medications to prevent or treat cytokine release syndrome (CRS) or other toxicitieswere more frequently used in the real-world setting than what had been seen in clinical trials. Medications, such as steroids and/or tocilizumab (Actemra), which is a common medication used to treat CRS, were used much more in the real-world setting than in clinical trials, concludes Kansagra.

Recent Videos
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Related Content
© 2024 MJH Life Sciences

All rights reserved.